No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

Long-term outcomes of higher- vs. lower-dose radiation therapy

There is still no absolute clarity to the degree of benefit associated with higher-dose as opposed to older, lower-dose external beam radiation therapy for men with localized prostate cancer. … READ MORE …

Does statin therapy really extend survival of men diagnosed with prostate cancer?

An analysis of another large cohort of prostate cancer patients (this time from the United Kingdom) has again suggested that there is a reduction in the risk of prostate cancer-specific mortality for patients who are treated with statins after their initial diagnosis with prostate cancer. … READ MORE …

Ability to project long-term response to treatment with abiraterone acetate + prednisone

A report published yesterday on the OncLive web site discusses a presentation by Dr. Howard Scher at the 2013 European Cancer Congress in Amsterdam. Dr. Scher reported that a panel of biomarkers could identify men with metastatic, castration-resistant prostate cancer (mCRPC) who were responding well or less well to treatment with abiraterone + prednisone. … READ MORE …

New study links quality of life data to median overall survival in prostate cancer

An “exploratory study”, published recently in BMC Urology, offers us evidence that men with prostate cancer who have less baseline fatigue and those whose dyspnea and cognitive functioning improves within 3 months of treatment have a significantly increased probability of survival. … READ MORE …

Can metformin extend survival of prostate cancer patients with (or without) diabetes?

A retrospective analysis of data from  > 3,800 Canadian men has suggested that diabetic men who also had prostate cancer and were being treated with a commonly used, generic drug called metformin have a reduced risk for death from prostate cancer. … READ MORE …

Baseline data from the control arm of the STAMPEDE trial

One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,132 other followers